Jason O’Byrne, MBA

Jason O’Byrne, MBA

Executive Vice President and Chief Financial OfficeratVir Biotechnology· In proxies 2024–2025

Pay in FY2025+2% from the year before · Vir Biotechnology stock -17.8% the same year

Jason O’Byrne, MBA was paid $2.0M in FY2025 (Dec), up 2%. Vir Biotechnology stock fell 17.8% that year.

Pay$100 in the stock at the end of FY23 → $60
Pay is from the Summary Compensation Table of each Vir Biotechnology proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Vir BiotechnologyPublic company · 2 yr
    • Executive Vice President and Chief Financial Officer2024 – Present · 2 yrStock in role +17%

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?